DNB

Dun & Bradstreet

DNB

Delisted

DNB was delisted on the 7th of February, 2019.

Back to rankings

Financials Financial Data & Stock Exchanges

Financial journalist opinion

Nexis Solutions Integrates Dun & Bradstreet's Comprehensive AI-Ready Business Data to Boost Customer Decision-Making

Dun & Bradstreet's proprietary corporate data complements LexisNexis' repository of legal data and licensed news content – including the industry's largest collection of GenAI-approved news datasets Dun & Bradstreet's proprietary corporate data complements LexisNexis' repository of legal data and licensed news content – including the industry's largest collection of GenAI-approved news datasets

Nexis Solutions Integrates Dun & Bradstreet's Comprehensive AI-Ready Business Data to Boost Customer Decision-Making

Zacks Investment Research

Dun & Bradstreet (DNB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Dun & Bradstreet (DNB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Dun & Bradstreet (DNB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Dun & Bradstreet (DNB) Lags Q2 Earnings and Revenue Estimates

Dun & Bradstreet (DNB) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.23 per share a year ago.

Dun & Bradstreet (DNB) Lags Q2 Earnings and Revenue Estimates

Dun & Bradstreet Unveils D&B Healthcare Insights to Help Sales and Marketing Teams Across Industries Unlock Opportunities in the Healthcare Ecosystem

D&B Healthcare Insights, Available as an Add-On to D&B Hoovers, Elevates Sales & Marketing Strategies to Drive Commercial Success JACKSONVILLE, Fla. , July 31, 2025 /PRNewswire/ -- Dun & Bradstreet (NYSE:DNB), a leading global provider of business data and analytics, today announced the launch of D&B Healthcare Insights, a powerful new dataset designed to help sales and marketing teams uncover growth opportunities and make smarter, faster decisions across the healthcare ecosystem.

Dun & Bradstreet Unveils D&B Healthcare Insights to Help Sales and Marketing Teams Across Industries Unlock Opportunities in the Healthcare Ecosystem

Chorus Intelligence Collaborates with Dun & Bradstreet to Integrate Global Business Data into the Chorus Intelligence Suite

LONDON , July 15, 2025 /PRNewswire/ -- Chorus Intelligence Ltd ('Chorus'), a leading provider of advanced digital intelligence and investigations software, is excited to join forces with Dun & Bradstreet (NYSE:DNB), a leading global provider of business decisioning data and analytics to integrate their comprehensive global business data into the Chorus Intelligence Suite (CIS). This collaboration provides banking, financial services, law enforcement, and government organisations with seamless access to Dun & Bradstreet's extensive global business data—directly within the CIS—enhancing investigative capabilities with business intelligence.

Chorus Intelligence Collaborates with Dun & Bradstreet to Integrate Global Business Data into the Chorus Intelligence Suite

Dun & Bradstreet Global Survey of 10,000 Executives Uncovers Intensifying Strategic Risks Across Supply Chains, Trade and Investment Flows

Persistent macroeconomic uncertainty and supply chain vulnerabilities drive decline in business confidence for a third consecutive quarter JACKSONVILLE, Fla. , July 8, 2025 /PRNewswire/ -- Dun & Bradstreet (NYSE: DNB), a leading global provider of business data and analytics, today released its Global Business Optimism Insights report, demonstrating the lowest level of optimism for the upcoming quarter since late 2023.

Dun & Bradstreet Global Survey of 10,000 Executives Uncovers Intensifying Strategic Risks Across Supply Chains, Trade and Investment Flows

Zacks Investment Research

Should Value Investors Buy Dun & Bradstreet (DNB) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Dun & Bradstreet (DNB) Stock?

Zacks Investment Research

All You Need to Know About Dun & Bradstreet (DNB) Rating Upgrade to Buy

Dun & Bradstreet (DNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Dun & Bradstreet (DNB) Rating Upgrade to Buy

Zacks Investment Research

Are Investors Undervaluing Dun & Bradstreet (DNB) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Dun & Bradstreet (DNB) Right Now?

SHAREHOLDER BUYOUT ALERT: Kaskela Law LLC Announces Fairness Investigation Into Dun & Bradstreet Holdings, Inc. (NYSE: DNB) Proposed Stockholder Buyout and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) (“DNB”) shareholders. Click here for additional information: https://kaskelalaw.com/case/dun-bradstreet/. On March 24, 2025, DNB announced that it had agreed to be acquired by private equity firm Clearlake Capital Group, L.P. at a price of $9.15 per share in cash. Following the closing of the p.

SHAREHOLDER BUYOUT ALERT: Kaskela Law LLC Announces Fairness Investigation Into Dun & Bradstreet Holdings, Inc. (NYSE: DNB) Proposed Stockholder Buyout and Encourages Investors to Contact the Firm

See News Rankings

Charts implemented using Lightweight Charts™